AU Stock MarketDetailed Quotes
IMC Immuron Ltd
- 0.100
- 0.0000.00%
20min DelayMarket Closed Aug 9 15:52 AET
22.80MMarket Cap-5882P/E (Static)
0.000High0.000Low0Volume0.000Open0.100Pre Close0.00Turnover0.17052wk High0.00%Turnover Ratio228.00MShares0.06552wk Low-0.017EPS TTM18.86MFloat Cap673.436Historical HighLossP/E (Static)188.57MShs Float0.050Historical Low-0.017EPS LYR0.00%Amplitude--Dividend TTM1.30P/B1Lot Size--Div YieldTTM
About Immuron Ltd Company
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
Company Profile
SymbolIMC
Company NameImmuron Ltd
Founded1994
MarketASX
Employees6
Fiscal Year Ends06-30
AddressChapman Street Unit 10, 25-37
CityMelbourne
CountryAustralia
Zip Code3130
Phone+61 398245254
Websitehttps://www.immuron.com.au
Share RegistryAUTOMIC REGISTRY SERVICES
Level 5, 126 Phillip Street, SYDNEY, NSW, AUSTRALIA, 2000
Company Executives
- Name
- Position
- Salary
- Steven Lydeamore
- Chief Executive Officer
- 580.57K
- Dr. Jerry Kanellos, PhD
- Chief Operating Officer
- 313.09K
- Phillip A. Hains
- Chief Financial Officer and Secretary
- --
- Flavio Palumbo
- Chief Commercial Officer
- 217.60K
- Paul Brennan
- Chairman of the Board
- 132.17K
- Professor Ravi Savarirayan
- Independent Director
- 70.00K
- Stephen Anastasiou
- Independent Director
- 70.00K
- Daniel Pollock
- Independent Director
- 104.98K
- Dr. Roger Aston
- Independent Director
- 116.03K
Analysis
Price Target
No Data
Heat List
AU
Overall
Symbol
Latest Price
% Chg